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Abstract
Background: The diabetic foot ulcer (DFU) is one of the most prevalent complications of diabetes mellitus and
often develops severe effects that can lead to amputation. A non-healing “minor” amputation often precedes a
major amputation resulting in a negative impact on the function and quality of life of the patients. Stem cell-based
therapies have emerged as a promising option to improve healing, and the adipose tissue is an abundant and easy
to access source. The injection of autologous micro-fragmented adipose tissue at the amputation stump of a diabetic
population undergoing a lower limb minor amputation was evaluated and compared with the standard care.
Methods: In this randomized controlled trial with two arms (parallel assignment) and no masking, 114 patients
undergoing a lower limb minor amputation were randomized to standard of care or to micro-fragmented
adipose tissue injection prepared using a minimal manipulation technique (Lipogems®) in a closed system.
Clinical outcomes were determined monthly up to 6months. Primary endpoint of the study was the evaluation of
the healing rate and time after the minor amputation. Secondary endpoints included the assessment of safety,
feasibility, technical success, relapse rate, skin tropism, and intensity of pain.
Results: At 6 months, 80% of the micro-fragmented adipose tissue-treated feet healed and 20% failed as compared
with the control group where 46% healed and 54% failed (p = 0.0064). No treatment-related adverse events nor
relapses were documented, and technical success was achieved in all cases. The skin tropism was improved in the
treatment group, and the pain scale did not differ between the two groups.
Conclusion: The results of this randomized controlled trial suggest that the local injection of autologous micro-
fragmented adipose tissue is a safe and valid therapeutic option able to improve healing rate following minor
amputations of irreversible DFU. The technique overcomes several stem cell therapy-related criticisms and its
potential in wound care should be better evaluated and the therapeutic indications could be expanded.
Trial registration: ClinicalTrials.gov number: NCT03276312. Date of registration: September 8, 2017 (retrospectively
registered).
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Introduction
Diabetes mellitus is a rapidly increasing chronic disease
that has a significant impact on the communities’ health
[1]. A common complication of this pathology is the de-
velopment of chronic lower extremity ulcers, with the
diabetic foot ulcer (DFU) being the most prevalent [2, 3].
A DFU often develops severe complications such as infec-
tion, which can lead to amputation and prolonged
hospitalization. Every year, more than 1 million people are
subjected to amputation due to DFU, and this number is
underestimated taking into account the lack of a national
registry in developing countries [1]. A non-healing digital
or transmetatarsal “minor” amputation (DA; TMA) often
precedes a major amputation resulting in a negative
impact on the function and quality of life of the patients
[4, 5]. A major amputation means physical disability and
also psychological/psychiatric problems, with significant
increase in the mortality rate, which is estimated to range
from 10 to 50% and from 30 to 80% at 1 and 5 years post-
amputation, respectively [6–9]. The DFU has been esti-
mated to account for 12–15% of the overall financial re-
sources destined to the management/treatment of
diabetes [7–9]. The financial burden reverts on the pa-
tients, society, and the National Health System, and con-
sidering its not negligible amount, it becomes imperative
to reduce the number of major amputations. That said,
improving the stump healing following minor amputa-
tions seems to be reasonable and cost-effective.
Stem cell-based therapies have emerged as a promising
therapeutic strategy to improve the healing process
[10–13]. The attraction is additionally boosted by the
absence of strong evidences able to demonstrate the
superiority of any other specific conservative treat-
ment or dressing [14]. Through trophic, immunomod-
ulatory, and anti-microbial actions, mesenchymal stem
cells (MSCs) “sense” and “signal” changes in the
microenvironment where they reside by serving as
paracrine mediators [11, 15, 16]. The adipose tissue is
an abundant source of MSCs (ASCs), easy to access
and simple to harvest [17, 18]. Both in vitro and in
vivo studies showed favorable results and confirmed
their anti-inflammatory and regenerative properties
[11, 19–21]. To overcome the complex regulatory issues
linked to the enzymatic treatment and/or cell expansion
[22–25], a minimally manipulated autologous adipose tis-
sue is a promising and safe option [26].
The commercially available Lipogems® system is a class
II-a medical device intended for the closed-loop process-
ing and transferring of autologous adipose tissue in a
single surgical step. This technology reduces the size of
the adipose tissue clusters by means of mild mechanical
forces while eliminating pro-inflammatory oil and
blood residue, intra-operatively providing mechanically
micro-fragmented adipose tissue in a short time without
expansion and/or enzymatic treatment [27]. Throughout
the overall procedure, the processed fat is only subjected
to slight mechanical forces without detrimental effects on
the integrity of the stromal vascular niche and the tissue
itself because the device is carefully prefilled with saline to
avoid the presence of air throughout all the steps. The
resulting product has been shown to possess reparative
properties, particularly when injected into inflammatory
or ischemic tissues [28] due to its capacity to induce vas-
cular stabilization and to inhibit several macrophage func-
tions involved in inflammation [29] and has been proven
to have potential applications in osteoarthritis, anal incon-
tinence, anal fistulas, low back pain, orthognathic surgical
corrections, and others [30–39].
To the best of our knowledge, there are no random-
ized trials evaluating the injection of micro-fragmented
adipose tissue at the amputation stump compared with
the standard care. Therefore, a randomized controlled
single-center clinical trial was performed in our de-
partment with the primary endpoint of assessing its
impact in terms of healing rate and time in a diabetic
population undergoing a lower limb minor amputa-
tion. Secondary endpoints included the safety, feasibil-
ity, technical success, relapse rate, skin tropism, and
pain grading up to 6 months. It has to be highlighted
that micro-fragmented adipose tissue has been exten-
sively studied in other clinical areas and a number of
published evidences showed no safety or feasibility
concerns [30, 31, 33–35, 40].
Materials and methods
Study design and population
This is a randomized controlled single-center clinical
trial (MiFrAADiF) with two arms (parallel assignment)
and no masking. The trial has been performed (enroll-
ment, treatment, clinical assessments, and result ana-
lyses) between 7 April 2015 and 31 March 2018 at the
Diabetic Foot Service in the Vascular Surgery Depart-
ment of the University of Modena and Reggio Emilia,
Modena, Italy.
Patients were selected according to the following in-
clusion criteria (Fig. 1): patients with diabetes mellitus
(types 1 and 2) of both sexes, age > 18 years old, and
presence of irreversible digital/forefoot ulcer/gangrene
(with negative X-ray for osteolytic lesions). Adequate cir-
culation (perfusion) was assessed by transcutaneous oxy-
gen test ≥ 30 mmHg, ankle brachial index ≥ 0.7, and
pressure index finger/arm toe/brachial index ≥ 0.6. Dop-
pler arterial waveforms were triphasic or biphasic at the
ankle of the affected leg. Patients who had undergone
previous oncological treatments (past 5 years) or on-
going and/or neoplastic lesions, under corticosteroid
therapy, with active vascular issues or inadequate lower
extremity perfusion were excluded. Eligible patients were
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randomized 1:1 to local injection of autologous micro-
fragmented adipose tissue (treatment group) or to stand-
ard clinical practice (control group) after a lower limb
minor amputation.
Randomization—sequence generation
Randomization used a paper block system. Sheets of
paper in blocks of ten with five sheets having an assign-
ment of treatment and the other five having the assign-
ment of control were placed in a blank sealed envelope.
The envelopes were shuffled and then labeled 1 through
10. This process was observed by the principal investiga-
tor and study staff. The investigators did not have know-
ledge of the process used to create the assignments, and
randomization of patients proceeded individually at their
first post-screening treatment.
Surgical procedure
The care of all the patients as well as the amputa-
tions was carried out in accordance with the inter-
national standards [7]. All procedures were performed
in an operating theater. Local or regional anesthesia
and eventual superficial sedation were performed by
the anesthesiologist. Patients from both arms were
subjected to DA or TMA minor amputation. The stumps
were closed by primary intention. After amputation, pa-
tients were treated as follows:
A) Treatment group. In the same surgical session, the
lower/lateral abdomen or the inner/outer thigh was
chosen as the donor site. Both donor and distal site
were cleaned with chlorhexidine. Prior to harvest,
the donor site was injected with 100 mL of Klein
Solution (500 mL saline, 1 mL epinephrine 1/1000
IU, and 40 mL lidocaine 2%) using a disposable 17-
gauge cannula connected to a 60-mL Luer lock
syringe. The fat was then harvested (50–100 mL)
using a 13-gauge cannula connected to a 20-ml
VacLok® syringe. The lipoaspirated tissue was
immediately processed in the Lipogems® processing
kit (Lipogems International Spa, Milan, Italy) as
previously described [27].
Lipogems® is a disposable device that mechanically
reduces the size of the adipose tissue clusters while
Fig. 1 MiFrAADiF trial flow diagram, inclusion and exclusion criteria
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eliminating oily substances and blood residues in a
complete immersion of physiological solution to
minimize any mechanical-related trauma on the
cells. The device consists of a cylindric processing
unit which contains five stainless steel marbles, an
input and an output sieve, a saline input line, an
access port with Luer lock connection to load the
lipoaspirate, a drainage line, a second access port
with Luer-lock connection to unload the processed
material, and a collection bag for waste fluid. The
processing unit, filled with normal saline solution is
maintained in flow condition by gravity. After saline
priming, adipose tissue inserted in the device
undergoes a first cluster reduction and micronization
by means of the input sieve. The mechanical action
exerted by shaking the stainless steel marbles in the
processing unit allows emulsion of the lipid mass and
consequently the reduction of the clusters. The
continuous flow of normal saline solution eliminates
residues of oil emulsion and any remaining blood
components. The second adipose cluster reduction is
obtained by passing the floating adipose clusters
through a second-size reduction filter. At the end of
the procedure, the device releases a micro-fragmented
fluid fat tissue product (clusters of 300–600 μm in
diameter) that can easily pass through a small caliber
needle. The processed micro-fragmented fat was
collected in a 60-mL syringe to decant, and the excess
of saline solution was eliminated. The final product
was injected radially into the bed of the amputation in
an amount dependent on the extension of the stump
within a range of 10 to 30mL. The entire process was
carried out in sterile conditions into the operating
theater.
The medication was carried out after cleaning with
sodium hypochlorite and saline solution, using
paraffin gauze with a povidone-iodine solution (10%
of iodine). Compressive medication was applied to
the site of fat harvesting for the following 48 h.
Patients were kept under observation and discharged
from the hospital with the instruction of absolute rest
and unloading on the limb until the next control.
B) Control group. The medication was carried out
after cleaning with sodium hypochlorite and saline
solution, using paraffin gauze with a povidone-iodine
solution (10% of iodine).
Patients were kept under observation and
discharged from the hospital with the instruction
of absolute rest and unloading on the limb until
the next control.
Follow-up, outcomes, and definitions
All the patients were clinically assessed within 20 days
from surgery and monthly for 6 months thereafter.
At each visit (enrollment and follow-up), the patients
were clinically evaluated [7] and asked to grade pain
through the visual analogue scale (VAS). All the visits
were performed by a selected group of experienced phy-
sicians (RL, SG, RS) and dedicated investigators (NL,
GTB, TC) who simultaneously gathered the data on a
case report form (paper and electronic).
The DAs (finger or trans-phalangeal) and the TMAs
(up to midfoot) were considered minor amputations.
The primary objective of the MiFrAADiF trial was the
evaluation of healing rate and time of the minor amputa-
tions treated with autologous micro-fragmented adipose
tissue compared with standard of care in case of irrevers-
ible DFU with resolved peripheral arterial disease.
Healing was defined as complete re-epithelialization of
the stump by primary intention, as determined by at
least 2 investigators. A visit was conducted 7–10 days
after healing to confirm the result. Failure was consid-
ered a stump dehiscence requiring any kind of foot re-
operation (revision, secondary minor or major amputa-
tion), infected or non-healing amputation at the end of
the follow-up.
Secondary outcomes included the assessment of the
safety, the feasibility, the technical success, the relapse
rate, the skin tropism, and the intensity of pain. Safety
was assessed by recording type and incidence of any ad-
verse event and complications occurring during the
follow-up, discriminating the likely relationship between
the complication and the technique. Feasibility was
intended as any technical issue encountered in adipose
tissue harvesting, processing, and injection in the ampu-
tation stump. The technical success was considered
achieved in case of absence of issues precluding the pro-
cedure. Relapse was defined as clinically assessed stump
re-dehiscence after a “false” healing. The skin tropism of
the stump was assessed by a combined evaluation of the
perilesional skin (graded as undamaged, erythematous,
macerated, atrophic) and of the lesion’s edge (graded as
undamaged, erythematous, callous, macerated, necrotic).
All these items were graded (0 cm, 1 cm, 1.5 cm, > 2 cm),
and the sum was used to evaluate the tropism of the
skin. Pain was assessed with the VAS.
Sample size calculation and statistical methods
The correct sample size was calculated considering as
primary endpoint a benefit in terms of a 50% reduction
in the healing time. The mean healing time for a lesion
is generally 4 months; thus, a reduction to 2 months can
be considered a clinically relevant benefit. Considering a
dropout of 10% by setting a level of significance alpha =
0.05 and a power of 1 − beta = 0.80, 57 patients for each
arm were required.
The primary endpoint, i.e., the difference in the heal-
ing time between the two groups, has been calculated by
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log rank test and Kaplan-Meier curves. Secondary out-
comes have been analyzed by appropriate one-way
ANOVA with Bonferroni’s post-test for continuous
variables after normality assessment by Kolmogorov-
Smirnoff test. To test the influence of multiple variables
on continuous data, two-way ANOVA has been per-
formed with Bonferroni’s post-test. For categorical vari-
ables, Fisher’s exact test was applied. All these analyses
were performed using GraphPad Prism v7.0 (GraphPad
Software, La Jolla, CA, USA).
A multivariate logistic regression analysis was applied
to identify influencing factors, using R software (R Foun-
dation, Vienna, Austria). A p value < 0.05 was considered
statistically significant and a p < 0.1 was considered as
tendency.
Ethics
The MiFrAADiF trial was conducted under Local Ethics
Committee approval (protocol no. 2621/C.E.). The writ-
ten consent and the case report form were reviewed by
the Local Ethics Committee. The participants’ written
consent was obtained prior to the enrollment. The trial
was registered in ClinicalTrials.gov (NCT03276312) and
conducted in compliance with applicable regulatory
requirements in accordance with the revised provisions
of the Helsinki Declaration and in adherence with Good
Clinical Practice. Confidentiality was maintained with all
patient records.
Results
A total of 373 subjects were screened, and the 114 meet-
ing the inclusion criteria were enrolled and randomized
1:1 to micro-fragmented adipose tissue injection (treat-
ment group, n = 57) or standard of care (control group,
n = 57) (Fig. 1). Patients and amputations’ level baseline
characteristics were similar (Table 1).
At 6 months, 80% (n = 44/55) of the micro-fragmented
adipose tissue-treated feet healed and 20% (n = 11/55)
failed as compared with the control group where 46%
(n = 23/50) healed and 54% (n = 27/50) failed (p = 0.0064
treatment vs. control).
Apart from micro-fragmented adipose tissue, also con-
comitant therapies such as oral hypoglycemic agents
(p < 0.05) and antibiotics (p < 0.05) positively correlated
with healing. On the other hand, the presence of cardiac
pathologies, chronic respiratory insufficiency, hemodialysis,
and age were found as negative factors but only for the
treatment group (p < 0.05, p < 0.05, p < 0.05, and p = 0.08,
respectively).
The healing time did not differ between the 2 groups,
resulting in an average of 2.8 months (SD 1.3 months) in
the treatment group and 2.8 months (SD 1.0 month) in
the control group. On the contrary, the healing probability
during time was significantly improved in the treatment
group with respect to the control group (p < 0.001, Fig. 2).
In addition, patients with a digital lesion appeared to re-
cover faster (within the fourth follow-up visit; p = 0.034).
As shown in Fig. 1, seven deaths not treatment-related
were documented during this trial (2 in the treatment
group and 5 in the control group). In addition, two pa-
tients from the control group discontinued intervention
due to voluntary withdrawal. Two procedure-related







Standard deviation 11.6 10.8
Gender
Male 45 (79%) 41 (72%)
Female 12 (21%) 16 (28%)
First treatment
Yes 49 (86%) 53 (93%)
No 8 (14%) 4 (7%)
Type of amputation
Digital 49 (86%) 49 (86%)
Transmetatarsal 8 (14%) 8 (14%)
Related pathologies 53 (93%) 57 (100%)
Hypertension 50 (88%) 50 (88%)
Chronic renal failure 20 (35%) 28 (49%)
Hemodialysis 6 (10%) 1 (2%)
Heart diseases 35 (61%) 43 (75%)
Neurological disorders 2 (4%) 8 (14%)
Autoimmune disorders 1 (2%) –
Chronic respiratory failure 9 (16%) 14 (25%)
Others 9 (16%) 10 (18%)
Smoke
Yes 11 (20%) 8 (14%)
Former 23 (40%) 24 (42%)
No 23 (40%) 25 (44%)
Concomitant therapies 57 (100%) 57 (100%)
Oral anticoagulant 8 (14%) 15 (26%)
Antiplatelet 53 (93%) 53 (93%)
Insulin 37 (65%) 46 (81%)
OHAs 32 (56%) 25 (44%)
NSAIDs 8 (14%) 9 (16%)
Opioid 6 (10%) 7 (12%)
Antibiotics 10 (18%) 6 (10%)
Others 7 (12%) 3 (5%)
Continuous data are presented as means and standard deviation. Categorical
data are given as counts (%)
OHAs oral hypoglycemic agents, NSAIDs non-steroidal anti-inflammatory drugs
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complications were registered (2 hematoma of the ab-
dominal wall, site of adipose tissue harvesting); one was
resolved with compressive dressing, and the second re-
quired a surgical incision to achieve hemostasis of the
subcutaneous tissue. Both patients were prior assuming
oral anticoagulant medication.
Technical success was achieved in all cases, and no
technical issues precluded the completion of the proced-
ure. The extremely fluid fat easily passed through fine
sharp needles (21 up to 25 G) and was distributed uni-
formly in the bed of the amputation.
No relapses have been observed in both study groups.
Regarding skin tropism, no correlation between perile-
sional skin or lesion’s edge at baseline and healing or
failure has been detected. The skin tropism appeared to
be improved in the treatment group because healing im-
provement was achieved in a higher number of patients
as compared to control.
The VAS scale did not differ between the groups at
any follow-up visit (Fig. 3). The improvement of this
parameter was registered in both groups since the
second visit with respect to the preoperative values.
The pain reduction was mainly influenced by the time
(p < 0.001), and the treatment with micro-fragmented
adipose tissue demonstrated a significant contribution
to this effect (p < 0.05).
Discussion
The healing of the amputations performed in case of
diabetic foot ulcers (DFU), both digital (DA) and trans-
metatarsal “minor” amputation (TMA), represents a
challenge. The high burden of the disease [1], meaning
millions of people losing quality of life, and the elevated
costs to health providers [9] are the leading factors
pushing medical research.
The present randomized controlled trial compared the
injection of autologous micro-fragmented adipose tissue
(treatment group) at the amputation site compared with
standard care primarily aiming at improving the healing
rate in such arduous clinical setting. The presence of
mesenchymal stem cells within the adipose tissue (ASCs)
and the promising results documented in the treatment
of different pathologies [30–35] prompted our group to
evaluate the efficacy of this innovative technique in improv-
ing stump healing after a lower limb minor amputation.
The pathophysiology of the DFU includes microcirculatory
damages and growth factor alterations, plus other mecha-
nisms that keep the wound in an inflammatory phase [41].
The beneficial role of ASCs has been demonstrated by
many authors [18–20, 42, 43]. The multi-potent differenti-
ation capability together with the strong paracrine action of
these cells represent an interesting therapeutic chance to
increase healing [10–13] and to treat the commonly under-
lying arterial disease.
The technique we selected in this trial requires lipoas-
piration, which has been used for decades in plastic sur-
gery with a very low incidence of major complications
[44]. The absence of procedure-related death and
major adverse events allowed us to confirm the safety
of both the lipoaspiration and the injection of the au-
tologous micro-fragmented adipose tissue in the am-
putation stump.
The present study provided a significantly higher heal-
ing rate of the treatment group compared with the
control (80% vs. 46%, p = 0.0064) which was totally un-
expected considering a recent meta-analysis [5] that re-
ported a re-amputation rate exceeding 55% following
TMA. Our results were obtained excluding from the
study second intention healing and healing after 6
months, two common resolution of minor amputations.
Moreover, not all the patients analyzed in the meta-
analysis were diabetics and the inclusion criteria were
not precise [5]. In the present authors’ opinion, all of
these aspects make the results of MiFrAADiF study even
more interesting.
A clinical evaluation of the skin tropism was per-
formed at each follow-up visit, but this outcome can be
affected by plenty of confounding factors and several
considerations have to be made. A unique exam testing
the skin tropism validated by the scientific community is
not available. The standardization of a clinical evaluation
Fig. 2 Kaplan-Meier showing healing probability over time
Fig. 3 Kaplan-Meier showing visual analogue scale (VAS) over time
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is still difficult in spite of the fact that these assessments
were performed by a selected team of experienced physi-
cians being part of our Diabetic foot service using a
standard case report form. The skin tropism appeared to
be improved in the treatment group just because healing
improvement was achieved with such a big difference
compared to control.
Pain assessment represented another secondary out-
come of the present study. No significant differences be-
tween the 2 groups were found at each follow-up visit
using the VAS pain scale. Anyway, the treatment group
had a reduction of pain in a significant shorter time. The
no-difference in pain grading could be of no surprise if
we consider that the high prevalence of diabetics suffer
symptoms of distal polyneuropathy [45]. The patho-
physiology of this phenomenon and the correlation with
DFU is not yet completely understood [45]. Specific
publications about pain after minor amputations for
DFU are not available, partially due to the use of health-
related quality of life tools. These tools combine phys-
ical, mental, and social health data including pain grad-
ing. It is difficult to discern specific amputation related
from the neuropathic pain in such complex patients, es-
pecially in the “acute” phase of the amputation. Further-
more, lifestyle and pharmacological interventions are
not able to treat completely neuropathic pain and its
evolution has been defined “not predictable” in a recent
review [45]. The intra-articular injection of autologous
micro-fragmented adipose tissue in osteoarthritic pa-
tients has been demonstrated to significantly improve
the VAS scale [40]. It is the authors’ opinion that these
findings are encouraging and probably our not statisti-
cally significant results were biased by the overlapping
neuropathy and the well-known confounding factors af-
fecting the DFU.
The major re-amputation rate was reported to range
from 0 to 56% in a review focused on TMA (including
non-diabetic patients) [5], and the rate reached 63% con-
sidering all the re-operations. Published data on TMA
outcomes led some authors to doubt the primary TMA
approach in lieu of minor amputations [5]. The failure
rate in the present trial (re-amputations, re-operations,
not-healing stump at final follow-up) was 20% in the
treatment and 54% in the control group. In addition, the
oral hypoglycemic agents and antibiotics were found to
be correlated. The prevalence of type II diabetic patients
in this trial led us to hypothesize that patients taking in-
sulin had an overall worse disease compared with OHAs
patients and tent toward worse results. Obviously, this is
a speculation and future studies are mandatory.
To conclude, the DFU is a tough clinical and medical
field. The MiFrAADiF trial demonstrated the extremely
high benefit of the injection of autologous micro-
fragmented adipose tissue in terms of healing. This is a
partial answer to the continuous demand of randomized
controlled trials focused on regenerative therapies that
still dominate the wound healing scientific community.
Several factors were taken into account when planning
the trial with micro-fragmented adipose tissue: the har-
vesting is safe and simple [44], the mechanical fragmen-
tation avoids laboratory manipulation of the product
(e.g., enzymatic treatment), the use of minimally manip-
ulated autologous adipose tissue complies with ethics
laws, the immunological rejection could be avoided
without heterologous and/or allogeneic material, and
injecting the graft at the stump level avoids possible
complications related to the endovascular delivery [13].
The results lead us to confirm the abovementioned posi-
tive features, in particular, the intra/perilesional injection
was safe and feasible in a wide range of stumps (DA/
TMA). Because the trial focused on the feasibility and
efficacy of a product obtained with a commercially avail-
able device, a fine morphological analysis of the injected
material was not within the aims of the study. Further-
more, the injected micro-fragmented adipose tissue has
been widely studied and characterized in vitro by other
authors [27, 29, 46–48] and published data indicate that
it contains an abundant number of cells able to act
through a paracrine mechanism to prime and sustain an-
giogenic, anti-fibrotic, anti-inflammatory, and immuno-
modulatory responses in the target tissue. The number
of injected cells was not assessed because it is a hard
technical issue, due to the presence of cell aggregates
upon collagenase digestion that prevent an exact cell
count. It should be highlighted however that micro-
fragmented adipose tissue is a complex matrix that con-
tains not only MSCs but also many other active ele-
ments embedded in a natural scaffold that preserves
them from a rapid degradation in vivo. Thus, the num-
ber of injected MSCs cannot be simplistically assumed
as a measurement of efficiency. Application of micro-
fragmented adipose tissue in experimental animal ische-
mic disease models has shown some beneficial effects
mediated by the capability of its MSC content to release
vasculogenic/angiogenic and anti-inflammatory mole-
cules [28, 29]. An in vitro study of its angiogenic activity
demonstrated that it significantly reduces adhesion mol-
ecule (AM) expression (ICAM-1 and VCAM-1) and im-
proves cord-like formation, indicating a preferential
ability to favor vascular stability and maturation.
The analysis of the secretome indicated a high content
of both angiopoietin-1 and angiopoietin-2 and low levels
of vascular endothelial growth factor (VEGF) and matrix
metalloproteinase-2 (MMP2). In addition, the cultured
micro-fragmented adipose tissue releases in its culture
medium a number of anti-inflammatory factors. Indeed,
it reduced migration, adhesion to an activated endothe-
lial cell monolayer, and the release of Regulated upon
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activation normal T cell expressed and presumably se-
creted (RANTES) and monocyte chemotactic protein-1
(MCP-1) chemokines of U937, monocytes of tumori-
genic origin used as a valid model to investigate the in-
flammatory properties of monocytes. These data indicate
that micro-fragmented adipose tissue in vitro is able to
block several important monocyte inflammatory func-
tions [28, 49].
It must be taken into account that the impairment of
the angiogenic/differentiation potential of the autologous
stem cells in diabetes still represents an issue to be in-
vestigated [50].
All that said, the commercially available Lipogems®
system has been demonstrated to be easy-to-use (no
technical failure), quick (short procedural time), and ver-
satile (no specific characteristics in the patient are re-
quired). The kit-related costs seem to be inferior to
more complex stem cell manipulation systems. Regard-
less of the initial cost, future publications should evalu-
ate the hypothesis of a reduction of the global economic
burden due to the application of autologous micro-
fragmented adipose tissue in the treatment of DFU.
The present study is not without limitations due to the
absence of blinding which represents the most import-
ant critical issue. Unfortunately, the “waste” harvesting
of adipose tissue is not ethically acceptable because of its
invasiveness. In addition, the funding constraints and
the volume of the center forced us to limit the study
sample size. Although the sample size calculation indi-
cated that the number of patients we enrolled and
treated was sufficient, a higher number of patients in a
multicenter setting would have been preferable from a
clinical point of view. The number of MSCs was not
assessed in order to evaluate the “quality” of the micro-
fragmented adipose tissue of each patient, and to the
best author knowledge, the optimal amount of stem cells
to inject is not yet defined [50].
Future work should clarify if the impressive healing re-
sults reported above correlate with a reduction of the
hospitalization time and of the overall health-related
costs. These perspectives could have an even more posi-
tive impact on patients’ quality of life and on the health
providers’ policy. Further points to be addressed should
be the impact of the technique on pain, encompassing
pathophysiological study to understand the overlap with
neurological disorders.
Conclusions
The single-center, prospective, controlled, and random-
ized design represents the strengths of the present work
and the gold standard in order to minimize investigator,
selection, and information bias as well as to manage
confounding factors.
Our experience with autologous micro-fragmented
adipose tissue has proven to be a valid therapeutic op-
tion able to drastically improve healing following minor
amputations performed on DFU. The present technique
overcomes several stem cell therapy-related criticism
and its potential in wound care should be better evalu-
ated and the therapeutic indications could be expanded.
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